ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Friday, November 13th. The stock was sold at an average price of $70.80, for a total transaction of $35,400.00. Following the completion of the transaction, the vice president owned 72,924 shares in the company, valued at approximately $5,163,019.20. The trade was a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Tuesday, October 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $73.59, for a total transaction of $36,795.00.
- On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total transaction of $35,395.00.
ANI Pharmaceuticals Trading Up 0.5%
ANIP stock traded up $0.38 during trading on Friday, hitting $71.44. 383,853 shares of the company traded hands, compared to its average volume of 474,006. The company has a 50-day moving average of $72.32 and a 200-day moving average of $77.00. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 2.75. ANI Pharmaceuticals, Inc. has a 1 year low of $67.14 and a 1 year high of $87.76. The firm has a market capitalization of $1.62 billion, a PE ratio of 14.23, a P/E/G ratio of 2.29 and a beta of 0.45.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52. The business had revenue of $290.78 million for the quarter, compared to analysts’ expectations of $280.59 million. ANI Pharmaceuticals had a return on equity of 28.34% and a net margin of 11.22%. The business’s quarterly revenue was up 27.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.04 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ANI Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Versant Capital Management Inc raised its holdings in shares of ANI Pharmaceuticals by 103.3% during the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 217 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $32,000. USA Financial Formulas purchased a new stake in ANI Pharmaceuticals in the third quarter worth $39,000. Finally, Sterling Capital Management LLC lifted its stake in ANI Pharmaceuticals by 850.0% in the third quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock worth $50,000 after acquiring an additional 612 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Wednesday, November 4th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price target for the company. Guggenheim increased their price target on shares of ANI Pharmaceuticals from $119.00 to $121.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Oppenheimer began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $100.00.
Get Our Latest Research Report on ANI Pharmaceuticals
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.
Further Reading
- Five stocks we like better than ANI Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
